menu search

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says
Source: Streetwise Reports (11/11/22) With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts. For a biopharma with one new drug candidate on the verge of potential approval in the U.S. and a second close behind, Aldeyra Therapeutics Inc.(ALDX:NASDAQ) is currently […]... Read More
Posted: Nov 14 2022, 14:22
Author Name: investmacro
Views: 103177

Search within

Pages Search Results: